Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study

Vano, YA; Phan, L; Gravis, G; Korakis, I; Schlurmann, F; Maillet, D; Bennamoun, M; Houede, N; Topart, D; Borchiellini, D; Barthelemy, P; Ratta, R; Ryckewaert, T; Hasbini, A; Hans, S; Emambux, S; Cournier, S; Braychenko, E; Elaidi, RT; Oudard, S

Vano, YA (通讯作者)，Ctr Univ Paris Cite, Hop Europeen Georges Pompidou, AP HP, Med Oncol, Paris, France.

INTERNATIONAL JOURNAL OF CANCER, 2022; 151 (8): 1335

Abstract

Nivolumab and cabozantinib are approved agents in mRCC patients after sunitinib/pazopanib (TKI) failure. However, the optimal sequence, cabozantinib t......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索